Nobiletin
CAS 478-01-3
Nobiletin (CAS 478-01-3) is a pharmaceutical compound with 5 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | GI50 | 45714.17152542373 nM | 59 | - |
| - | Potency | 22901.938461538462 nM | 31 | - |
| - | IC50 | 29819.41176470588 nM | 17 | - |
| - | AC50 | 100000 nM | 1 | - |
| - | IC50 | 0.01 ug.mL-1 | 1 | - |
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| ABCG2 ABCG2 |
Inhibition | 5.360000133514404 pIC50 | 21354800 |
| TAS2R14 TAS2R14 |
Agonist | 5.679999828338623 pEC50 | 28834122 |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Nobiletin used for in pharmaceutical contexts?
Nobiletin (CAS 478-01-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Nobiletin?
No adverse-event association or SIDER side-effect rows are rendered for Nobiletin in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Nobiletin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for NOBILETIN with EU status "permitted".
What clinical phase is Nobiletin in?
No phase 1-4 clinical development badge is rendered for Nobiletin because the matched compound identifier rows do not contain a max-phase value.